))
Off-Label Risks: Compliance Matters Now More Than Ever
Manage episode 421766467 series 3506216
Innhold levert av Darshan Kulkarni. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Darshan Kulkarni eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
We shed light on the complexities surrounding off-label promotion and reimbursement in the pharmaceutical industry.
We discuss the following:
- What does off-label mean from a reimbursement standpoint?
- Lessons from the US v. Eli Lilly 2009 case
- How do recent court decisions impact off-label promotion? United States v. Caronia and US v. Facteau
- How are weight loss drugs, initially approved for treating diabetes, reimbursed within Medicare and Medicaid?
- How are compounded drugs reimbursed?
- Could a company be held accountable for off-label use of a drug due to
- compounded products?
- Are weight loss drugs exempted from reimbursement?
109 episoder
Del
